Caplacizumab

Generic Name
Caplacizumab
Brand Names
Cablivi
Drug Type
Biotech
Chemical Formula
-
CAS Number
915810-67-2
Unique Ingredient Identifier
2R27AB6766
Background

Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.

Indication

Capacizumab is approved for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP) in conjunction with plasma exchange and immunosuppression in patients 18 years or older.

aTTP is a rare autoimmune condition presented by a disruption of blood clotting order which is translated into systemic microvascular thrombosis leading to profound thrombocytopenia, hemolytic anemia and organ ischemia. It is caused by the production of autoantibodies against ADAMTS-13 which is the protein in charge of cleaving the von-Wilebrand factor. The lack of this process produces the generation of ultra large von Wilebrand multimers that bind to platelets and form microthrombi and causing thromboembolic complications.

Previously, capacizumab was under review for the prevention of thrombosis in high-risk patients with acute coronary syndrome undergoing percutaneous coronary intervention but this indication was withdrawn.

Associated Conditions
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Associated Therapies
-

Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors

Not yet recruiting
Conditions
Interventions
First Posted Date
2024-04-10
Last Posted Date
2024-11-13
Lead Sponsor
US Thrombotic Microangiopathy Alliance
Target Recruit Count
116
Registration Number
NCT06358703
Locations
🇺🇸

USTMA, Groveport, Ohio, United States

A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)

First Posted Date
2023-03-27
Last Posted Date
2023-03-27
Lead Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Target Recruit Count
1
Registration Number
NCT05785468
Locations
🇮🇹

FPG, Roma, Italy

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

First Posted Date
2022-07-21
Last Posted Date
2024-07-03
Lead Sponsor
Sanofi
Target Recruit Count
61
Registration Number
NCT05468320
Locations
🇺🇸

Beth Israel Deaconess Medical Center Site Number : 8400005, Boston, Massachusetts, United States

🇺🇸

University of Minnesota Site Number : 8400013, Minneapolis, Minnesota, United States

🇺🇸

Duke University Medical Center Site Number : 8400022, Durham, North Carolina, United States

and more 49 locations

Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)

First Posted Date
2022-03-02
Last Posted Date
2022-12-14
Lead Sponsor
Sanofi
Target Recruit Count
4
Registration Number
NCT05263193
Locations
🇫🇷

Sanofi-Aventis, Chilly-Mazarin, France

Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP

First Posted Date
2021-01-22
Last Posted Date
2021-01-22
Lead Sponsor
University Hospital, Rouen
Target Recruit Count
125
Registration Number
NCT04720261
© Copyright 2024. All Rights Reserved by MedPath